These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31240499)

  • 1. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
    Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
    Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM
    Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Blachley T; Best JH; Zlotnick S; Reiss WG; Emeanuru K; Kremer JM
    Rheumatol Ther; 2021 Mar; 8(1):467-481. PubMed ID: 33630272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.
    Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM
    Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
    Haraoui B; Casado G; Czirják L; Taylor A; Bernasconi C; Reiss W; Caporali R
    Clin Exp Rheumatol; 2017; 35(6):899-906. PubMed ID: 28516886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.
    Harrold LR; John A; Reed GW; Haselkorn T; Karki C; Li Y; Best J; Zlotnick S; Kremer JM; Greenberg JD
    Rheumatol Ther; 2017 Dec; 4(2):405-417. PubMed ID: 28936808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
    Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
    Mease PJ; Stryker S; Liu M; Salim B; Rebello S; Gharaibeh M; Collier DH
    Arthritis Res Ther; 2021 Sep; 23(1):236. PubMed ID: 34496952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.
    Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C
    Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.
    Pappas DA; John A; Curtis JR; Reed GW; Karki C; Magner R; Kremer JM; Shewade A; Greenberg JD
    Rheumatol Ther; 2016 Jun; 3(1):103-115. PubMed ID: 27747515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.
    Verhoeven MM; de Hair MJ; Tekstra J; Bijlsma JW; van Laar JM; Pethoe-Schramm A; Borm ME; Ter Borg EJ; Linn-Rasker SP; Teitsma XM; Lafeber FP; Jacobs JW; Welsing PM
    Ann Rheum Dis; 2019 Oct; 78(10):1333-1338. PubMed ID: 31196844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.
    Gabay C; Riek M; Hetland ML; Hauge EM; Pavelka K; Tomšič M; Canhao H; Chatzidionysiou K; Lukina G; Nordström DC; Lie E; Ancuta I; Hernández MV; van Riel PL; van Vollenhoven R; Kvien TK
    Ann Rheum Dis; 2016 Jul; 75(7):1336-42. PubMed ID: 26374404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
    Weinblatt ME; Kremer J; Cush J; Rigby W; Teng LL; Devenport J; Singh N; Lepley D; Genovese MC
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.
    Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C
    Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.
    Karadag O; Farisogullari B; Yagiz B; Erden A; Ademoglu Z; Kimyon G; Bilge NS; Icacan OC; Kilic L; Coskun BN; Ersozlu ED; Kucuksahin O; Mercan R; Koca SS; Gonullu E; Cinar M; Akar S; Emmungil H; Kasifoglu T; Bes C; Omma A; Pehlivan Y; Kiraz S; Ertenli I; Dalkilic E; Kalyoncu U
    Clin Exp Rheumatol; 2024 Jan; 42(1):130-137. PubMed ID: 37650346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.
    Saraux A; Rouanet S; Flipo RM; Poncet JC; Fardellone P; Hilliquin P; Idier I; Cantagrel A
    Clin Exp Rheumatol; 2016; 34(2):303-10. PubMed ID: 26941130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Burmester GR; Rubbert-Roth A; Cantagrel A; Hall S; Leszczynski P; Feldman D; Rangaraj MJ; Roane G; Ludivico C; Bao M; Rowell L; Davies C; Mysler EF
    Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.